CD276 and non-small cell lung carcinoma: GNCs, anti-B7H3 scFv, and Dox were employed as the model carrier, targeting ligand, and drug, respectively, to fabricate B7H3 targeting Dox-conjugated GNCs (B7H3/Dox@GNCs) for precise spatial–temporal synchronization of chemotherapy-photothermal therapy against NSCLC (Scheme 1).